Price History

Hover for the daily close. The dotted line marks the period open.

Compare LKFT with… →

LKFT Key Statistics

As of Sep 4, 2026

Trading

Open: $28.65
Previous Close: $29.02
Day's Range: 28.38–29.04
52-Week Range: 25.68–37.78
Volume: 208.20K
Beta: 0.12

Valuation

Market Cap: $1.87B
P/E Ratio: 2.77
P/S ratio: 1.88
EPS (ttm): 10.27

Financials (FY)

Revenue (FY): $1.11B+303.50%
Net Income (FY): $320.88M+333.15%
Profit margin: 60.23%
Shares Outstanding: 65.48M
1-Year Return: −10.72%

Dividend and dates

Earnings Date: November 12, 2026
Avg Volume: 207.58K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LKFT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+125.45%−52.14%−12.87%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−12.87%
2025	+18.91%
2024	−32.35%
2023	−8.40%
2022	−19.50%
2021	−44.30%
2020	−52.14%
2019	+125.45%
2018	−2.15%
2017	+46.07%
2016 (partial year)	+19.09%

As of September 4, 2026.

LKFT Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$1.11B	$320.88M	28.9%
2024	$275.65M	$74.08M	26.9%
2023	$239.72M	$211.70M	88.3%
2022	$241.25M	−$217.99M	−90.4%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$1.11B	$1.08B	$501.39M	$320.88M	28.9%
2024	$275.65M	$240.79M	−$188.34M	$74.08M	26.9%
2023	$239.72M	$239.72M	−$88.26M	$211.70M	88.3%
2022	$241.25M	$241.25M	−$131.06M	−$217.99M	−90.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LKFT Valuation vs Biotechnology Median

Median of 656 stocks

Metric	LKFT	Biotechnology median	vs median
P/E	2.77	12.57	0.2x the median
P/S ratio	1.88	15.26	0.1x the median
Profit margin	60.23%	0.00%	60.2 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lakefront Biotherapeutics NV (LKFT) is capitalised at $1.87B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 196 employees.

The 52-week range on file runs from $25.68 to $37.78. LKFT last closed at $28.49 on September 4, 2026. That is −$0.53 (−1.83%) against the previous close. The latest close sits 10.94% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.11B. Against the prior fiscal year total of $275.65M, that is a change of +303.50%. The same year closed with net income of $320.88M. That is +333.15% against the prior fiscal year. Profit margin runs at 60.23%. That is 60.2 percentage points above the Biotechnology median of 0%. Earnings per share on a trailing basis come to 10.27.

Across the 4 fiscal years on file, revenue moves from $241.25M in 2022 to $1.11B in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

LKFT trades at a trailing price-to-earnings ratio of 2.77. That is 0.2 times the Biotechnology median of 12.57. The price-to-sales ratio is 1.88. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −10.72%. Measured over 10 years, that is −6.25% a year compounded. The reported beta is 0.12. Daily returns over the trailing 10 years annualize to a volatility of 38.01%.

Growth & Income

No dividend is on file for LKFT.

The strongest complete calendar year on file is 2019 at +125.45%; the weakest is 2020 at −52.14%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −12.87% year to date.

Peer Comparison

Lakefront Biotherapeutics NV (LKFT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Lakefront Biotherapeutics NV	LKFT	$1.87B	2.8
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Lakefront Biotherapeutics NV trades at a P/E of 2.8.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Visit website →

Lakefront Biotherapeutics NV (LKFT) Stock Analysis